|
Hydroxyurea Clinical Trials
7 actively recruiting trials across 6 locations
▲ +1 trial since August 2026
Also known as: Droxia, Hydrea, Hydroxycarbamide, ITF2357, Litalir +8 more
Pipeline
Phase 1: 2Phase 2: 3Phase 3: 1Phase 1/2: 1
Top Sponsors
- Paul Szabolcs2
- University of Chicago1
- Uma Borate1
- Theradex1
- Roswell Park Cancer Institute1
Indications
- Cancer5
- Systemic Juvenile Idiopathic Arthritis (sJIA)1
- Inflammatory Conditions1
- Hereditary Anemias1
- Inherited Metabolic Disorders (IMD)1
Pittsburgh, Pennsylvania2 trials
Phase 1/2
Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT
UPMC Children's Hospital of Pittsburgh
Phase 2
Birmingham, Alabama1 trial
Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera
University of Alabama at Birmingham
Phase 3
Tampa, Florida1 trial
Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia
Moffitt Cancer Center
Phase 2
Chicago, Illinois1 trial
Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer
The University of Chicago
Phase 1
Buffalo, New York1 trial
Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Roswell Park Cancer Institute
Phase 1
Columbus, Ohio1 trial
Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy
Ohio State University Comprehensive Cancer Center
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.